631 related articles for article (PubMed ID: 35239637)
41. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
42. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
[TBL] [Abstract][Full Text] [Related]
43. Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
Chapin-Bardales J; Myers T; Gee J; Shay DK; Marquez P; Baggs J; Zhang B; Licata C; Shimabukuro TT
Vaccine; 2021 Nov; 39(48):7066-7073. PubMed ID: 34763946
[TBL] [Abstract][Full Text] [Related]
44. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021.
Oliver SE; Wallace M; See I; Mbaeyi S; Godfrey M; Hadler SC; Jatlaoui TC; Twentyman E; Hughes MM; Rao AK; Fiore A; Su JR; Broder KR; Shimabukuro T; Lale A; Shay DK; Markowitz LE; Wharton M; Bell BP; Brooks O; McNally V; Lee GM; Talbot HK; Daley MF
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):90-95. PubMed ID: 35051137
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
[TBL] [Abstract][Full Text] [Related]
46. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
47. Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of Adolescents - United States, April 15-23, 2021.
Scherer AM; Gedlinske AM; Parker AM; Gidengil CA; Askelson NM; Petersen CA; Woodworth KR; Lindley MC
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(28):997-1003. PubMed ID: 34264908
[TBL] [Abstract][Full Text] [Related]
48. A Case Report of Sudden Sensorineural Hearing Loss (SSNHL) After Administration of the COVID-19 Vaccine.
Andrade J; Sessa L; Ephrat M; Truong J; DiGregorio R
J Pharm Pract; 2024 Jun; 37(3):753-757. PubMed ID: 36537083
[TBL] [Abstract][Full Text] [Related]
49. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021.
Hause AM; Gee J; Johnson T; Jazwa A; Marquez P; Miller E; Su J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):685-688. PubMed ID: 33956781
[TBL] [Abstract][Full Text] [Related]
50. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
51. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
Jacobs JW; Booth GS; Adkins BD
Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
[TBL] [Abstract][Full Text] [Related]
52. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR
Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898
[TBL] [Abstract][Full Text] [Related]
53. A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older.
Tamburro M; Ripabelli G; D'Amico A; De Dona R; Iafigliola M; Parente A; Samprati N; Santagata A; Adesso C; Natale A; Di Palma MA; Cannizzaro F; Sammarco ML
J Community Health; 2022 Oct; 47(5):814-821. PubMed ID: 35750980
[TBL] [Abstract][Full Text] [Related]
54. Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis.
Katoto PDMC; Brand AS; Byamungu LN; Tamuzi JL; Mahwire TC; Kitenge MK; Wiysonge CS; Gray G
Hum Vaccin Immunother; 2022 Nov; 18(6):2144039. PubMed ID: 36367429
[TBL] [Abstract][Full Text] [Related]
55. Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
Katherine Yih W; Daley MF; Duffy J; Fireman B; McClure D; Nelson J; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
Vaccine; 2023 Jan; 41(2):460-466. PubMed ID: 36481108
[TBL] [Abstract][Full Text] [Related]
56. In brief: Pfizer/BioNTech COVID-19 vaccine authorized for children 5-11 years old.
Med Lett Drugs Ther; 2021 Nov; 63(1638):185. PubMed ID: 35085214
[No Abstract] [Full Text] [Related]
57. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
[TBL] [Abstract][Full Text] [Related]
59. COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years - United States, December 14, 2020-July 31, 2021.
Murthy BP; Zell E; Saelee R; Murthy N; Meng L; Meador S; Reed K; Shaw L; Gibbs-Scharf L; McNaghten AD; Patel A; Stokley S; Flores S; Yoder JS; Black CL; Harris LQ
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(35):1206-1213. PubMed ID: 34473680
[TBL] [Abstract][Full Text] [Related]
60. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
Malden DE; Gee J; Glenn S; Li Z; Mercado C; Ogun OA; Kim S; Lewin BJ; Ackerson BK; Jazwa A; Weintraub ES; McNeil MM; Tartof SY
Vaccine; 2023 Jan; 41(2):315-322. PubMed ID: 36351861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
